Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 8, 1263 - 1269 (2002)
Published online: 15 October 2002 | doi:10.1038/nm790
Therapeutically effective antibodies against amyloid-
peptide target amyloid- residues 4–10 and inhibit cytotoxicity and fibrillogenesis
J. McLaurin1,2, R. Cecal3, M.E. Kierstead1,2, X. Tian3, A.L. Phinney1, M. Manea3, J.E. French1, M.H.L. Lambermon1, A.A. Darabie1, M.E. Brown1, C. Janus1, M.A. Chishti1, P. Horne1, D. Westaway1,2, P.E. Fraser1,4, H.T.J. Mount1,5, M. Przybylski3 & P. St George-Hyslop1,5
Abstract
Immunization of transgenic mouse models of Alzheimer disease using amyloid-
peptide (A) reduces both the Alzheimer disease–like neuropathology and the spatial memory impairments of these mice. However, a therapeutic trial of immunization with A42 in humans was discontinued because a few patients developed significant meningo-encephalitic cellular inflammatory reactions. Here we show that beneficial effects in mice arise from antibodies selectively directed against residues 4–10 of A42, and that these antibodies inhibit both A fibrillogenesis and cytotoxicity without eliciting an inflammatory response. These findings provide the basis for improved immunization antigens as well as attempts to design small-molecule mimics as alternative therapies.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
